TG Therapeutics

$30.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.80 (+2.71%) Today

+$0.51 (+1.68%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell TGTX and other stocks, options, and ETFs commission-free!

About TGTX

TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. The listed name for TGTX is TG Therapeutics, Inc. Common Stock.

CEO

Michael Sean Weiss

Employees

134

Headquarters

New York, New York

Founded

1993

Market Cap

3.98B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.29M

High Today

$31.65

Low Today

$29.71

Open Price

$29.95

Volume

1.35M

52 Week High

$31.97

52 Week Low

$6.34

Collections

Analyst Ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

TGTX Earnings

-$0.73

-$0.49

-$0.24

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 1, After Hours